Anti-TB drug ‘could reduce HIV/AIDS deaths’

A pharmacy at a TB clinic in Ghana Copyright: Pierre Virot / World Lung Foundation

By: Gideon Munaabi

We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:

You have to credit our authors.
You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
The easiest way to get the article on your site is to embed the code below.

For more information view our media page and republishing guidelines.

The full article is available here as HTML.

Press Ctrl-C to copy

<div class="article-wrap">
<div id="article-introduction">
<h1>Anti-TB drug ‘could reduce HIV/AIDS deaths’</h1>
<h4>By: Gideon Munaabi</h4>
</div>
<br />
<br />

<div id="article-body">
<p><P>[KAMPALA] A South African tuberculosis expert has called for a cheap and readily available drug for tuberculosis prevention to be given to all HIV-positive children not receiving antiretroviral treatment.</P><br />
<P>Tuberculosis (TB) is a widespread infection in developing countries and can exist in two forms: latent and active. People with HIV/AIDS are particularly susceptible to developing the active form of TB.</P><br />
<P>But the antibiotic isoniazid, or INH, can prevent this from happening for people living with HIV but who are not taking antiretroviral drugs (ARVs).</P><br />
<P>The World Health Organization currently recommends that isoniazid be given to HIV-positive children exposed to a household contact with TB.</P><br />
<P>However recent research indicates that INH can halve the number of deaths due to AIDS related illnesses for HIV-positive children, regardless of household situation.</P><br />
<P>Heather Zar, a paediatrician at the University of Cape Town in South Africa, and colleagues administered isoniazid to 263 HIV-positive children either daily or three times a week. </P><br />
<P>The team observed a 50 per cent reduction in the number of deaths and a 70 per cent reduction in the number of TB cases among the children, said Zar.</P><br />
<P>Their results were published in the British Medical Journal on 3 November.</P><br />
<P>“I think this is a very important study,” Zar told SciDev.Net. “The treatment  was found to reduce mortality and TB incidence greatly — which is very novel and very different to the way in which INH has been used before.” </P><br />
<P>She said the study has potentially large public health implications, adding that a strong case could be made for using INH in HIV-infected children who are not on ARVs and live in high TB prevalence areas. </P><br />
<P>Most children they studied were not on AIDS treatment, says Zar, explaining that the team are still waiting for results of an ongoing study in children on ARVs. </P><br />
<P>Earlier this year American researchers warned that INH would lose its effectiveness in the future as its widespread use may speed the emergence of drug-resistant forms of TB (see ‘<a  href="/News/index.cfm?fuseaction=readnews&itemid=2792&language=1" target=_self rel="noopener noreferrer">Warning over drug for patients with TB and HIV</A>‘).</P><br />
<P>But Zar said that so far, resistance had only been found in people already infected with TB and who were given INH by mistake, instead of receiving TB treatment. </P><br />
<P>“Before putting any child or adult on [preventive treatment] it is important to screen for and exclude TB, which requires treatment with three or four drugs,” she said.</P><br />
<P>The rise of TB in developing countries, especially in Africa, is in part related to the prevalence of HIV/AIDS.</P><br />
<P>In Uganda, where TB surged by 150 per cent between 2003 and 2004, 20 per cent of TB patients are also HIV-positive. </P><a  href="http://www.bmj.com/cgi/content/abstract/bmj.39000.486400.55v1" target="_blank" onclick="pageTracker._trackPageview('/tracking/external/'+this.href);" rel="noopener noreferrer">Link to abstract of research paper in the British Medical Journal</A><BR><BR><br />
<P>329, 110 (2004).<BR>Reference: British Medical Journal, doi: 10.1136/bmj.39000.486400.55 (2006) <BR><BR></P></p>

</div>
<div class="quick-links-wrapper">
<h3>You might also like</h3>
[related-articles]
</div>
<p>This article was originally published on <a href="https://www.scidev.net" target="_blank">SciDev.Net</a>. Read the <a href="https://www.scidev.net/asia-pacific/news/antitb-drug-could-reduce-hivaids-deaths-seaap/" target="_blank">original article</a>.</p>
<script type="text/javascript">
(function(e,t,n,r,i,s,o){e["GoogleAnalyticsObject"]=i;e[i]=e[i]||function(){(e[i].q=e[i].q||[]).push(arguments)},e[i].l=1*new Date;s=t.createElement(n),o=t.getElementsByTagName(n)[0];s.async=1;s.src=r;o.parentNode.insertBefore(s,o)})(window,document,"script","//www.google-analytics.com/ga.js","ga");var _gaq=_gaq||[];var _gaq=_gaq||[];_gaq.push(["_setAccount","UA-3223906-8"],["_trackEvent","article interaction","republished","https://www.scidev.net/asia-pacific/news/antitb-drug-could-reduce-hivaids-deaths-seaap/",null,true])
</script>
</div>

[KAMPALA] A South African tuberculosis expert has called for a cheap and readily available drug for tuberculosis prevention to be given to all HIV-positive children not receiving antiretroviral treatment.

Tuberculosis (TB) is a widespread infection in developing countries and can exist in two forms: latent and active. People with HIV/AIDS are particularly susceptible to developing the active form of TB.

But the antibiotic isoniazid, or INH, can prevent this from happening for people living with HIV but who are not taking antiretroviral drugs (ARVs).

The World Health Organization currently recommends that isoniazid be given to HIV-positive children exposed to a household contact with TB.

However recent research indicates that INH can halve the number of deaths due to AIDS related illnesses for HIV-positive children, regardless of household situation.

Heather Zar, a paediatrician at the University of Cape Town in South Africa, and colleagues administered isoniazid to 263 HIV-positive children either daily or three times a week.

The team observed a 50 per cent reduction in the number of deaths and a 70 per cent reduction in the number of TB cases among the children, said Zar.

Their results were published in the British Medical Journal on 3 November.

“I think this is a very important study,” Zar told SciDev.Net. “The treatment was found to reduce mortality and TB incidence greatly — which is very novel and very different to the way in which INH has been used before.”

She said the study has potentially large public health implications, adding that a strong case could be made for using INH in HIV-infected children who are not on ARVs and live in high TB prevalence areas.

Most children they studied were not on AIDS treatment, says Zar, explaining that the team are still waiting for results of an ongoing study in children on ARVs.

Earlier this year American researchers warned that INH would lose its effectiveness in the future as its widespread use may speed the emergence of drug-resistant forms of TB (see ‘Warning over drug for patients with TB and HIV‘).

But Zar said that so far, resistance had only been found in people already infected with TB and who were given INH by mistake, instead of receiving TB treatment.

“Before putting any child or adult on [preventive treatment] it is important to screen for and exclude TB, which requires treatment with three or four drugs,” she said.

The rise of TB in developing countries, especially in Africa, is in part related to the prevalence of HIV/AIDS.

In Uganda, where TB surged by 150 per cent between 2003 and 2004, 20 per cent of TB patients are also HIV-positive.

Link to abstract of research paper in the British Medical Journal

329, 110 (2004).
Reference: British Medical Journal, doi: 10.1136/bmj.39000.486400.55 (2006)